Compare Citius Pharmaceuticals Inc (CTXR) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Texas Instruments Incorporated — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while Texas Instruments Incorporated trades at $284.1 (market cap $256.11B). The key difference: Texas Instruments Incorporated is far larger — about 13673.8× Citius Pharmaceuticals Inc's market cap, and Texas Instruments Incorporated pays a 2.03% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | TXN | |
|---|---|---|
Market Cap | $18.73M | $256.11B |
Sector | Health | Technology |
52-Week High | $1.82 | $332.35 |
52-Week Low | $0.48 | $153.33 |
Enterprise Value | $14.95M | $263.16B |
Dividend Yield | — | 2.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Texas Instruments (TXN) trades at $281.24, down 1.69% over 24 hours, with a bullish technical signal from moving averages and recent price action above the 20-day average. Revenue grew to $17.68 billion in 2025, with net income of $5.00 billion and strong profitability margins. Recent news highlights CFO transition and AI-driven demand boosting data center revenue.
Outlook remains positive with analyst consensus price target of $333.10, implying 18% upside. Risks include high valuation multiples and increasing debt-to-asset ratio. The stock presents opportunity from AI infrastructure growth but faces margin pressure and competitive threats.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
